Examination of the usefulness of the genetic test of Circulating tumor cells (CTCs) in patients with gastrointestinal cancer (Circle-1, Circle-2 Trial)

Examination of the usefulness of the genetic test of Circulating tumor cells (CTCs) in patients with gastrointestinal cancer (Circle-1, Circle-2 Trial) - Circle-1, Circle-2 Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014095

Enrollment

Registered

2014-06-01

Start date

2013-05-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

clinical stage IV gastrointestinal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Circle 1: 1) Histologically proven gastrointestinal cancer (esophageal cancer, gastric cancer, colorectal cancer), and clinically judged adaptation of systemic chemotherapy 2) Aged 20 or more 3) Written informed consent Circle 2: 1) Histologically proven gastrointestinal cancer (esophageal cancer, gastric cancer, colorectal cancer, GIST), and clinically judged adaptation of systemic chemotherapy 2) Aged 20 or more 3) Systemic chemotherapy using molecular targeted durg is planned 4) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Positive HIV antibody 2) Positive HBs antigen, HCV antibody 3) Positive TP antibody 4) Inadequate physical condition, as diagnosed by primary physician

Design outcomes

Primary

Measure	Time frame
Circle-1: concordance rate in genetic mutational status in primary tumors and their corresponding CTCs. Circle-2: correlation between emergence of genetical mutations in CTCs and change in therapeutic effect during molecular targeted therapy.	—

Countries

Japan

Contacts

Public ContactShoji Hirokazu

National Cancer Center Hospital Gastrointestinal Medical Oncology

hshouji@ncc.go.jp03-3542-2511

Outcome results